Arachidonic Acid.

EPA competes with arachidonic acid for the sn-2 position of membrane phospholipids and for cyclooxygenase and lipoxygenase, and yields the three-series eicosanoids instead of the two-series. Raising one lowers what the other can produce, which is the classic omega-6 to omega-3 balance.

DHA incorporates into the same phospholipid pools and displaces arachidonic acid from membranes, lowering the substrate pool released by phospholipase A2. This is the intended effect of an omega-3 dose and the reason the two are counted against each other.

Fish oil delivers both competing long-chain omega-3 fatty acids at once, so it shifts membrane composition and eicosanoid output away from the arachidonic branch. A formula carrying both is working against itself on that axis.

Linoleic acid is desaturated and elongated through gamma-linolenic and dihomo-gamma-linolenic acid to arachidonic acid. It is the dietary source of the whole pool when arachidonic acid is not supplied directly.

GLA elongates to dihomo-gamma-linolenic acid, which competes with arachidonic acid at cyclooxygenase and yields the one-series eicosanoids. Part of the DGLA pool also converts onward to arachidonic acid, so the pairing moves in both directions.

Arachidonic acid carries four double bonds and is among the most peroxidation-prone fatty acids in the membrane. Alpha-tocopherol sits in the same bilayer and terminates the lipid radical chain, which is why tocopherol is added to any highly unsaturated oil.

Arachidonic acid is held esterified at the sn-2 position of membrane phosphatidylcholine and phosphatidylinositol and is released on demand by phospholipase A2. Phospholipid supply is what the acyl chain is loaded into.

Delta-6 desaturase, the rate-limiting step converting linoleic acid toward arachidonic acid, depends on zinc. Low zinc slows the whole elongation sequence.

Delta-6 desaturase activity also depends on vitamin B6 alongside zinc and magnesium. The cofactor set governs how much dietary linoleic acid reaches the arachidonic pool.

Cytosolic phospholipase A2 needs a calcium rise to translocate to the membrane and cleave arachidonic acid from the sn-2 position. Release, not supply, is the controlled step and it is calcium gated.

Salicin from willow bark is converted to salicylate, which damps cyclooxygenase activity and the thromboxane and prostaglandin output downstream of arachidonic acid. The substrate is still present but less of it moves down that branch.

Boswellic acids act on 5-lipoxygenase, the enzyme that converts arachidonic acid into the leukotriene series. It leaves the cyclooxygenase branch alone, so it shifts rather than blocks the metabolism of the same substrate.

Chain elongation of linoleic acid toward arachidonic acid runs through ATP-dependent elongase steps, and the biologically active form of ATP is the magnesium complex. Magnesium is therefore a background requirement for the whole desaturase and elongase sequence rather than a booster of it. This is settled biochemistry, not a supplementation finding.

Delta-6 and delta-5 desaturase are non-heme iron enzymes, so iron status sits upstream of how much arachidonic acid the body makes from dietary linoleic acid. Low iron availability slows the conversion step rather than blocking dietary intake of preformed arachidonic acid. The relationship is enzymatic and does not imply that extra iron raises tissue levels.

Riboflavin becomes FAD, the flavin cofactor for cytochrome b5 reductase that feeds electrons to the fatty acid desaturases. The same flavin pool also runs glutathione reductase, which keeps the antioxidant system that protects polyunsaturated fatty acids in the reduced state. Both roles are textbook cofactor chemistry.

Glutathione peroxidase 4 is a selenoenzyme that reduces the lipid hydroperoxides formed when membrane arachidonic acid is oxidised. Selenium availability therefore sets part of the ceiling on how well a highly unsaturated fatty acid is handled in membranes. This describes handling of the molecule, not an added effect on any outcome.

Glutathione is the reducing substrate that glutathione peroxidase uses to convert lipid hydroperoxides back to alcohols, and it also participates in the conversion of leukotriene A4 to leukotriene C4. Arachidonic acid metabolism therefore draws on the glutathione pool in two separate directions. Both steps are established enzymology.

Long-chain fatty acids, arachidonic acid included, cross the inner mitochondrial membrane only after conjugation to carnitine by the carnitine palmitoyltransferase system. Carnitine availability is a condition for beta-oxidation of the fraction that is not esterified into phospholipids. It has no bearing on eicosanoid formation, which happens outside the mitochondrion.

Reduced coenzyme Q10 acts as a lipid-phase antioxidant inside membranes and regenerates alpha-tocopherol after it quenches a lipid radical. Membranes rich in a four-double-bond fatty acid are the ones most exposed to chain peroxidation. The pairing is about protecting the lipid, not about changing how much arachidonic acid is present.

Dihydrolipoic acid regenerates ascorbate and glutathione, which in turn regenerate tocopherol at the membrane surface. That recycling network is what keeps polyunsaturated fatty acids from propagating oxidation chains. The link is mechanistic and does not rest on a combination trial.

Ascorbate reduces the tocopheroxyl radical back to alpha-tocopherol at the aqueous face of the membrane, restoring the main chain-breaking protector of esterified arachidonic acid. Vitamin C itself does not enter the membrane, so its role is regenerative rather than direct. Standard redox biochemistry.

Astaxanthin spans the lipid bilayer with its polar ends anchored at both surfaces, which is the structural reason it quenches radicals along the whole membrane thickness. Formulators pair carotenoids with highly unsaturated oils for oxidative stability of the finished product. The evidence base here is chemical and formulation-level, not clinical.

Alpha-linolenic acid from flaxseed and linoleic acid compete for the same delta-6 desaturase, so a large alpha-linolenic load reduces the share of enzyme capacity that goes toward arachidonic acid synthesis. This is substrate competition at a single enzyme and is one of the better characterised interactions in fatty acid metabolism. It is an anti-synergy worth flagging rather than a problem in itself.

Krill phospholipids deliver eicosapentaenoic and docosahexaenoic acid, which compete with arachidonic acid for esterification into membrane phospholipids and for access to cyclooxygenase and lipoxygenase. The measurable consequence is a shift in the membrane fatty acid ratio, which is a marker and not an outcome. Anyone combining the two is moving that ratio in opposite directions at once.

Gamma-linolenic acid in evening primrose oil is elongated to dihomo-gamma-linolenic acid, which delta-5 desaturase can convert onward to arachidonic acid. How much passes that last step varies, since dihomo-gamma-linolenic acid is also a substrate for its own series of mediators. The precursor relationship is established; the size of the flux in people is not.

Curcumin has been described as an inhibitor of cyclooxygenase-2 and 5-lipoxygenase activity in cell systems, the two enzymes that act on released arachidonic acid. Cell and enzyme work is what this rests on, so it belongs at a mechanistic confidence. Combining them pushes substrate and enzyme in opposite directions.

Gingerols and shogaols have been reported to reduce prostaglandin and leukotriene formation in cell-based assays by acting on the cyclooxygenase and lipoxygenase branches. That places ginger downstream of arachidonic acid rather than alongside it. The grounding is preclinical.

Quercetin has been described in vitro as an inhibitor of phospholipase A2 and lipoxygenase, the enzymes that release arachidonic acid from phospholipid and then oxygenate it. In vitro inhibition at assay concentrations does not establish what happens after oral intake. Read it as mechanistic rather than clinical.

Thromboxane A2, made from arachidonic acid in platelets, is the signal that amplifies platelet aggregation, and garlic constituents have been reported to reduce platelet aggregation through separate routes. Stacking agents that act on platelet function is worth flagging even when each one is modest on its own. This is a caution flag, not a benefit claim.

Arachidonic acid is stored esterified at the sn-2 position of membrane phosphoglycerides, and phospholipid material such as lecithin supplies the backbone pool that turnover draws on. In manufacturing, phospholipids also serve as emulsifiers for polyunsaturated oils. Both roles are structural rather than pharmacological.

Arachidonic acid appears in resistance-training stacks alongside protein powders, and the human work in this space has been done in trained men doing resistance exercise. Co-formulation is a convention of that category, not a demonstrated interaction. Anyone citing it should say so.

Both ingredients sit in the same training-support product category and are commonly taken together, but no trial has separated their contributions. Their mechanisms do not overlap: one is a phosphagen substrate, the other a membrane fatty acid. The pairing is formulation convention.